论文部分内容阅读
目的探讨造血细胞磷酸酶(SHP1)基因和天冬酰胺特异酶切的半胱氨酸蛋白酶(Caspase1、3)基因表达与白血病患者的化疗效果的关系。方法用RTPCR方法检测白血病患者骨髓单个核细胞中SHP1和Caspase1、3的mRNA表达。结果急性白血病(AL)患者SHP1和Caspase1、3表达率分别为33.3%、80.0%、100.0%;慢性髓细胞白血病(CML)患者SHP1表达率在急变期、慢性期分别为0.0%、37.5%。SHP1和Caspase1、3基因阳性患者的首次完全缓解(CR)率分别为85.0%、64.3%、55.8%,明显高于阴性患者(分别为15.6%、20.0%),差异均有统计学意义(P<0.05);Caspase1、3与SHP1表达呈正相关。结论SHP1可能是一个潜在的抑癌基因,它可能是通过激活下游的凋亡基因Caspase1、3发挥作用;Caspase1、3与SHP1基因表达呈正相关且与病人的CR率有关,表明它们均参与了白血病的转归,可同时作为判断白血病患者的疗效和预后指标。
Objective To investigate the relationship between the expression of hematopoietic cell phosphatase (SHP1) gene and asparagine-specific caspase-1 gene and the chemotherapeutic effect in leukemia patients. Methods RTPCR was used to detect the mRNA expression of SHP1 and Caspase1,3 in leukemia bone marrow mononuclear cells. Results The expression rates of SHP1 and Caspase1,3 in patients with acute leukemia (AL) were 33.3%, 80.0% and 100.0%, respectively. The rates of SHP1 expression in chronic myeloid leukemia (CML) were 0.0% and 37.5% respectively in acute and chronic phase. The first complete remission (CR) rates of SHP1 and Caspase1,3 positive patients were 85.0%, 64.3% and 55.8%, respectively, which were significantly higher than those of negative patients (15.6% and 20.0% respectively) (P <0.05). There was a positive correlation between Caspase1,3 and SHP1 expression. Conclusion SHP1 may be a potential tumor suppressor gene, which may play a role by activating the downstream apoptotic gene Caspase1,3; Caspase1,3 and SHP1 gene expression was positively correlated with the CR rate of patients, indicating that they are involved in leukemia Of the outcome, at the same time as a judge leukemia efficacy and prognosis indicators.